{"id":8360,"date":"2019-06-25T14:32:25","date_gmt":"2019-06-25T18:32:25","guid":{"rendered":"https:\/\/www.silverlaw.com\/blog\/?p=8360"},"modified":"2019-06-25T14:32:25","modified_gmt":"2019-06-25T18:32:25","slug":"nabriva-therapeutics-nbrv-subject-of-a-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/www.silverlaw.com\/blog\/nabriva-therapeutics-nbrv-subject-of-a-class-action-lawsuit\/","title":{"rendered":"Nabriva Therapeutics (NBRV) Subject Of A Class Action Lawsuit"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-medium wp-image-8361\" src=\"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2019\/06\/Pills2-300x200.jpg\" alt=\"Nabriva Therapeutics (NBRV), a publicly-traded biopharmaceutical company, is the subject of a class action lawsuit filed on behalf of shareholders who lost money investing in the company. Investors who purchased shares between November 1, 2018 and April 30, 2019 (the class period) may be eligible to participate in the lawsuit.\" width=\"300\" height=\"200\" srcset=\"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2019\/06\/Pills2.jpg 300w, https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2019\/06\/Pills2-180x120.jpg 180w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/>Nabriva Therapeutics (NBRV), a publicly-traded biopharmaceutical company, is the subject of a class action lawsuit filed on behalf of shareholders who lost money investing in the company.<\/p>\n<h3>Nabriva Class Period And Lead Plaintiff Deadline<\/h3>\n<p>Investors who purchased shares between November 1, 2018 and April 30, 2019 (the class period) may be eligible to participate in the lawsuit. <a href=\"https:\/\/www.silverlaw.com\/blog\/nabriva-therapeutics-nbrv-subject-of-a-class-action-lawsuit\/#more-8360\" class=\"more-link\">Continue reading \u203a<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nabriva Therapeutics (NBRV), a publicly-traded biopharmaceutical company, is the subject of a class action lawsuit filed on behalf of shareholders who lost money investing in the company. Investors who purchased shares between November 1, 2018 and April 30, 2019 (the class period) may be eligible to participate in the lawsuit.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[602,1646],"tags":[],"class_list":["post-8360","post","type-post","status-publish","format-standard","hentry","category-class-action","category-securities-fraud"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Nabriva Therapeutics (NBRV) Subject Of A Class Action Lawsuit<\/title>\n<meta name=\"description\" content=\"Nabriva Therapeutics (NBRV), a publicly-traded biopharmaceutical company, is the subject of a class action lawsuit filed on behalf of shareholders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.silverlaw.com\/blog\/nabriva-therapeutics-nbrv-subject-of-a-class-action-lawsuit\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Nabriva Therapeutics (NBRV) Subject Of A Class Action Lawsuit\" \/>\n<meta name=\"twitter:description\" content=\"Nabriva Therapeutics (NBRV), a publicly-traded biopharmaceutical company, is the subject of a class action lawsuit filed on behalf of shareholders.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2019\/06\/Pills2.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Silver Law Group\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nabriva Therapeutics (NBRV) Subject Of A Class Action Lawsuit","description":"Nabriva Therapeutics (NBRV), a publicly-traded biopharmaceutical company, is the subject of a class action lawsuit filed on behalf of shareholders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.silverlaw.com\/blog\/nabriva-therapeutics-nbrv-subject-of-a-class-action-lawsuit\/","twitter_card":"summary_large_image","twitter_title":"Nabriva Therapeutics (NBRV) Subject Of A Class Action Lawsuit","twitter_description":"Nabriva Therapeutics (NBRV), a publicly-traded biopharmaceutical company, is the subject of a class action lawsuit filed on behalf of shareholders.","twitter_image":"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2019\/06\/Pills2.jpg","twitter_misc":{"Written by":"Silver Law Group","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.silverlaw.com\/blog\/nabriva-therapeutics-nbrv-subject-of-a-class-action-lawsuit\/","url":"https:\/\/www.silverlaw.com\/blog\/nabriva-therapeutics-nbrv-subject-of-a-class-action-lawsuit\/","name":"Nabriva Therapeutics (NBRV) Subject Of A Class Action Lawsuit","isPartOf":{"@id":"https:\/\/www.silverlaw.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.silverlaw.com\/blog\/nabriva-therapeutics-nbrv-subject-of-a-class-action-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.silverlaw.com\/blog\/nabriva-therapeutics-nbrv-subject-of-a-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2019\/06\/Pills2-300x200.jpg","datePublished":"2019-06-25T18:32:25+00:00","author":{"@id":"https:\/\/www.silverlaw.com\/blog\/#\/schema\/person\/de64d999508b1ad10d608a99f0d2e752"},"description":"Nabriva Therapeutics (NBRV), a publicly-traded biopharmaceutical company, is the subject of a class action lawsuit filed on behalf of shareholders.","breadcrumb":{"@id":"https:\/\/www.silverlaw.com\/blog\/nabriva-therapeutics-nbrv-subject-of-a-class-action-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.silverlaw.com\/blog\/nabriva-therapeutics-nbrv-subject-of-a-class-action-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.silverlaw.com\/blog\/nabriva-therapeutics-nbrv-subject-of-a-class-action-lawsuit\/#primaryimage","url":"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2019\/06\/Pills2.jpg","contentUrl":"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2019\/06\/Pills2.jpg","width":300,"height":200,"caption":"Nabriva Therapeutics (NBRV), a publicly-traded biopharmaceutical company, is the subject of a class action lawsuit filed on behalf of shareholders who lost money investing in the company. Investors who purchased shares between November 1, 2018 and April 30, 2019 (the class period) may be eligible to participate in the lawsuit."},{"@type":"BreadcrumbList","@id":"https:\/\/www.silverlaw.com\/blog\/nabriva-therapeutics-nbrv-subject-of-a-class-action-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.silverlaw.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Nabriva Therapeutics (NBRV) Subject Of A Class Action Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.silverlaw.com\/blog\/#website","url":"https:\/\/www.silverlaw.com\/blog\/","name":"Securities Arbitration Lawyers Blog","description":"Published by Securities Arbitration Lawyers \u2014 Silver Law Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.silverlaw.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.silverlaw.com\/blog\/#\/schema\/person\/de64d999508b1ad10d608a99f0d2e752","name":"Silver Law Group","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.silverlaw.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9eb0a691642ae95c68ee1c45b5f50f35bae76a41f3d9f861c7bfd40c87661746?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9eb0a691642ae95c68ee1c45b5f50f35bae76a41f3d9f861c7bfd40c87661746?s=96&d=mm&r=g","caption":"Silver Law Group"}}]}},"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/posts\/8360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/comments?post=8360"}],"version-history":[{"count":1,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/posts\/8360\/revisions"}],"predecessor-version":[{"id":8362,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/posts\/8360\/revisions\/8362"}],"wp:attachment":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/media?parent=8360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/categories?post=8360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/tags?post=8360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}